Janssen Pharms patents expiration
1. Axert patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5565447 | JANSSEN PHARMS | Indole derivatives |
May, 2015
(8 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5565447 (Pediatric) | JANSSEN PHARMS | Indole derivatives |
Nov, 2015
(8 years ago) | |
Drugs and Companies using ALMOTRIPTAN MALATE ingredient
Market Authorisation Date: 07 May, 2001
Treatment: Treatment of migraine
Dosage: TABLET;ORAL
AXERT family patents
2. Concerta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9029416 | JANSSEN PHARMS | Methods and devices for providing prolonged drug therapy |
Jul, 2017
(6 years ago) | |
| US6930129 | JANSSEN PHARMS | Methods and devices for providing prolonged drug therapy |
Jul, 2017
(6 years ago) | |
| US6919373 | JANSSEN PHARMS | Methods and devices for providing prolonged drug therapy |
Jul, 2017
(6 years ago) | |
| US8163798 | JANSSEN PHARMS | Methods and devices for providing prolonged drug therapy |
Jul, 2017
(6 years ago) | |
| US9144549 | JANSSEN PHARMS | Methods and devices for providing prolonged drug therapy |
Jul, 2017
(6 years ago) | |
| US9000038 | JANSSEN PHARMS | Methods and devices for providing prolonged drug therapy |
Jul, 2017
(6 years ago) | |
| US8629179 | JANSSEN PHARMS | Methods and devices for providing prolonged drug therapy |
Jul, 2017
(6 years ago) | |
|
US6930129 (Pediatric) | JANSSEN PHARMS | Methods and devices for providing prolonged drug therapy |
Jan, 2018
(6 years ago) | |
|
US6919373 (Pediatric) | JANSSEN PHARMS | Methods and devices for providing prolonged drug therapy |
Jan, 2018
(6 years ago) | |
|
US9000038 (Pediatric) | JANSSEN PHARMS | Methods and devices for providing prolonged drug therapy |
Jan, 2018
(6 years ago) | |
|
US8629179 (Pediatric) | JANSSEN PHARMS | Methods and devices for providing prolonged drug therapy |
Jan, 2018
(6 years ago) | |
|
US8163798 (Pediatric) | JANSSEN PHARMS | Methods and devices for providing prolonged drug therapy |
Jan, 2018
(6 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-88) | Nov 04, 2012 |
Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient
Market Authorisation Date: 01 August, 2000
Treatment: Method of treating adhd; For claims 1-3,6-13,16-24 and 26-32: method of treating adhd; Method of treating adhd in children 6 years of age and older and adolescents
Dosage: TABLET, EXTENDED RELEASE;ORAL
CONCERTA family patents
3. Ditropan Xl patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5840754 | JANSSEN PHARMS | Dosage form comprising oxybutynin |
May, 2015
(8 years ago) | |
| US5912268 | JANSSEN PHARMS | Dosage form and method for treating incontinence |
May, 2015
(8 years ago) | |
| US5674895 | JANSSEN PHARMS | Dosage form comprising oxybutynin |
May, 2015
(8 years ago) | |
| US6262115 | JANSSEN PHARMS | Method for the management of incontinence |
May, 2015
(8 years ago) | |
|
US6262115 (Pediatric) | JANSSEN PHARMS | Method for the management of incontinence |
Nov, 2015
(8 years ago) | |
|
US5912268 (Pediatric) | JANSSEN PHARMS | Dosage form and method for treating incontinence |
Nov, 2015
(8 years ago) | |
|
US5840754 (Pediatric) | JANSSEN PHARMS | Dosage form comprising oxybutynin |
Nov, 2015
(8 years ago) | |
|
US5674895 (Pediatric) | JANSSEN PHARMS | Dosage form comprising oxybutynin |
Nov, 2015
(8 years ago) | |
Drugs and Companies using OXYBUTYNIN CHLORIDE ingredient
Market Authorisation Date: 16 December, 1998
Treatment: Management of incontinence, mgt of hormone replacement therapy, treatment of involuntary incontinence, mgt overactive bladder and increasing compliance in such pt
Dosage: TABLET, EXTENDED RELEASE;ORAL
DITROPAN XL family patents
4. Invega Hafyera patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11324751 | JANSSEN PHARMS | Dosing regimens associated with extended release paliperidone injectable formulations |
May, 2041
(17 years from now) | |
| US11304951 | JANSSEN PHARMS | Dosing regimens associated with extended release paliperidone injectable formulations |
May, 2041
(17 years from now) | |
| US11666697 | JANSSEN PHARMS | Methods for ensuring resuspension of paliperidone palmitate formulations |
Nov, 2041
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Strength(NS) | Aug 30, 2024 |
| New Product(NP) | May 18, 2018 |
Drugs and Companies using PALIPERIDONE PALMITATE ingredient
Market Authorisation Date: 30 August, 2021
Treatment: Treatment of schizophrenia by administering a dose up to two weeks before or three weeks after the scheduled six-month dose; Reinitiation of schizophrenia treatment wherein more than 6 months 3 weeks ...
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
INVEGA HAFYERA family patents
5. Invega Sustenna patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5254556 | JANSSEN PHARMS | 3-piperidinyl-1,2-benzisoxazoles |
Oct, 2013
(10 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5352459 | JANSSEN PHARMS | Use of purified surface modifiers to prevent particle aggregation during sterilization |
Dec, 2012
(11 years ago) | |
|
US5352459 (Pediatric) | JANSSEN PHARMS | Use of purified surface modifiers to prevent particle aggregation during sterilization |
Jun, 2013
(10 years ago) | |
|
US5254556 (Pediatric) | JANSSEN PHARMS | 3-piperidinyl-1,2-benzisoxazoles |
Apr, 2014
(10 years ago) | |
| US6077843 | JANSSEN PHARMS | Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters |
May, 2017
(6 years ago) | |
|
US6077843 (Pediatric) | JANSSEN PHARMS | Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters |
Nov, 2017
(6 years ago) | |
| US6555544 | JANSSEN PHARMS | Aqueous suspensions of submicron 9-hydroxyrisperidone fatty acid esters |
Nov, 2018
(5 years ago) | |
|
US6555544 (Pediatric) | JANSSEN PHARMS | Aqueous suspensions of submicron 9-hydroxyrisperidone fatty acid esters |
May, 2019
(4 years ago) | |
| US9439906 | JANSSEN PHARMS | Dosing regimen associated with long acting injectable paliperidone esters |
Jan, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2011 |
| New Indication(I-698) | Nov 12, 2017 |
| M(M-215) | Dec 20, 2020 |
| New Dosage Form(NDF) | Jul 31, 2012 |
| Pediatric Exclusivity(PED) | Jan 31, 2013 |
| M(M-119) | Aug 29, 2015 |
Drugs and Companies using PALIPERIDONE PALMITATE ingredient
NCE-1 date: 01 February, 2012
Market Authorisation Date: 31 July, 2009
Treatment: Treatment of schizophrenia; Dosing regimen for the treatment of schizophrenia in adults by administering two loading doses of paliperidone palmitate followed by maintenance dose(s)
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
INVEGA SUSTENNA family patents
6. Invega Trinza patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6077843 | JANSSEN PHARMS | Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters |
May, 2017
(6 years ago) | |
|
US6077843 (Pediatric) | JANSSEN PHARMS | Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters |
Nov, 2017
(6 years ago) | |
| US10143693 | JANSSEN PHARMS | Dosing regimen for missed doses for long-acting injectable paliperidone esters |
Apr, 2036
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Strength(NS) | Aug 30, 2024 |
| New Product(NP) | May 18, 2018 |
Drugs and Companies using PALIPERIDONE PALMITATE ingredient
Market Authorisation Date: 30 August, 2021
Treatment: Treatment of schizophrenia; Reinitiation of schizophrenia treatment following a missed dose more than 9 months ago
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
INVEGA TRINZA family patents
7. Invokamet patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7943788 | JANSSEN PHARMS | Glucopyranoside compound |
Jul, 2027
(3 years from now) | |
| US8513202 | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate |
Dec, 2027
(3 years from now) | |
| US7943582 | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate |
Feb, 2029
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8785403 | JANSSEN PHARMS | Glucopyranoside compound |
Jul, 2024
(3 months from now) | |
| US8222219 | JANSSEN PHARMS | Glucopyranoside compound |
Apr, 2025
(11 months from now) | |
| US11576894 | JANSSEN PHARMS | Combination therapy for the treatment of diabetes |
Jul, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 29, 2018 |
| New Indication(I-735) | May 20, 2019 |
| New Combination(NC) | Aug 08, 2017 |
| M(M-197) | Feb 01, 2020 |
| New Indication(I-788) | Oct 29, 2021 |
Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 29 March, 2017
Market Authorisation Date: 08 August, 2014
Treatment: Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; Reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascu...
Dosage: TABLET;ORAL
INVOKAMET family patents
8. Invokamet Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7943788 | JANSSEN PHARMS | Glucopyranoside compound |
Jul, 2027
(3 years from now) | |
| US8513202 | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate |
Dec, 2027
(3 years from now) | |
| US7943582 | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate |
Feb, 2029
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6723340 | JANSSEN PHARMS | Optimal polymer mixtures for gastric retentive tablets |
Oct, 2021
(2 years ago) | |
| US8785403 | JANSSEN PHARMS | Glucopyranoside compound |
Jul, 2024
(3 months from now) | |
| US8222219 | JANSSEN PHARMS | Glucopyranoside compound |
Apr, 2025
(11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Aug 08, 2017 |
| New Indication(I-735) | May 20, 2019 |
| New Chemical Entity Exclusivity(NCE) | Mar 29, 2018 |
| New Indication(I-788) | Oct 29, 2021 |
Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 29 March, 2017
Market Authorisation Date: 20 September, 2016
Treatment: Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; Reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascu...
Dosage: TABLET, EXTENDED RELEASE;ORAL
INVOKAMET XR family patents
9. Invokana patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7943788 | JANSSEN PHARMS | Glucopyranoside compound |
Jul, 2027
(3 years from now) | |
| US8513202 | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate |
Dec, 2027
(3 years from now) | |
| US7943582 | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate |
Feb, 2029
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8222219 | JANSSEN PHARMS | Glucopyranoside compound |
Apr, 2025
(11 months from now) | |
| US10617668 | JANSSEN PHARMS | Pharmaceutical formulations |
May, 2031
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-809) | Sep 27, 2022 |
| New Indication(I-733) | May 20, 2019 |
| M(M-197) | Feb 01, 2020 |
| New Indication(I-788) | Oct 29, 2021 |
| New Chemical Entity Exclusivity(NCE) | Mar 29, 2018 |
Drugs and Companies using CANAGLIFLOZIN ingredient
NCE-1 date: 29 March, 2017
Market Authorisation Date: 29 March, 2013
Treatment: Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diab...
Dosage: TABLET;ORAL
INVOKANA family patents
10. Levaquin patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6806256 | JANSSEN PHARMS | Taste masked liquid pharmaceutical compositions |
Feb, 2022
(2 years ago) | |
|
US6806256 (Pediatric) | JANSSEN PHARMS | Taste masked liquid pharmaceutical compositions |
Aug, 2022
(1 year, 8 months ago) | |
Drugs and Companies using LEVOFLOXACIN ingredient
Market Authorisation Date: 21 October, 2004
Treatment: NA
Dosage: SOLUTION;ORAL
LEVAQUIN family patents
11. Ortho Evra patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5972377 | JANSSEN PHARMS | Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen |
Jun, 2015
(8 years ago) | |
| US5876746 | JANSSEN PHARMS | Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen |
Nov, 2015
(8 years ago) | |
Drugs and Companies using ETHINYL ESTRADIOL; NORELGESTROMIN ingredient
Market Authorisation Date: 20 November, 2001
Treatment: Prevention of ovulation in a woman
Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL
ORTHO EVRA family patents
12. Ortho Tri-cyclen Lo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6214815 | JANSSEN PHARMS | Triphasic oral contraceptive |
Jun, 2019
(4 years ago) | |
|
US6214815 (Pediatric) | JANSSEN PHARMS | Triphasic oral contraceptive |
Dec, 2019
(4 years ago) | |
Drugs and Companies using ETHINYL ESTRADIOL; NORGESTIMATE ingredient
Market Authorisation Date: 22 August, 2002
Treatment: Contraception
Dosage: TABLET;ORAL-28
ORTHO TRI-CYCLEN LO family patents
13. Ponvory patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE43728 | JANSSEN PHARMS | Thiazolidin-4-one derivatives |
Nov, 2024
(6 months from now) | |
| US9062014 | JANSSEN PHARMS | Crystalline forms of (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-0-tolyl-thiazolidin-4-one |
May, 2032
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9000018 | JANSSEN PHARMS | Thiazolidin-4-one-derivatives |
Nov, 2024
(6 months from now) | |
| US8273779 | JANSSEN PHARMS | Thiazolidin 4-one derivatives |
Dec, 2025
(1 year, 7 months from now) | |
| US10220023 | JANSSEN PHARMS | Dosing regimen for a selective S1P1 receptor agonist |
Dec, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 18, 2026 |
Drugs and Companies using PONESIMOD ingredient
NCE-1 date: 18 March, 2025
Market Authorisation Date: 18 March, 2021
Treatment: Reduction of circulating lymphocytes in treating relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive dise...
Dosage: TABLET;ORAL
PONVORY family patents
14. Razadyne patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6099863 | JANSSEN PHARMS | Fast-dissolving galanthamine hydrobromide tablet |
Jun, 2017
(6 years ago) | |
| US6358527 | JANSSEN PHARMS | Fast-dissolving galanthamine hydrobromide tablet |
Jun, 2017
(6 years ago) | |
Drugs and Companies using GALANTAMINE HYDROBROMIDE ingredient
Market Authorisation Date: 28 February, 2001
Treatment: Treatment of alzheimer's dementia
Dosage: TABLET;ORAL
RAZADYNE family patents
15. Razadyne Er patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7160559 | JANSSEN PHARMS | Controlled release galantamine composition |
Dec, 2019
(4 years ago) | |
Drugs and Companies using GALANTAMINE HYDROBROMIDE ingredient
Market Authorisation Date: 01 April, 2005
Treatment: NA
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
RAZADYNE ER family patents
16. Risperdal patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5453425 | JANSSEN PHARMS | Risperidone oral formulation |
Jul, 2014
(9 years ago) | |
| USRE39181 | JANSSEN PHARMS | Aqueous risperidone formulations |
Jul, 2014
(9 years ago) | |
| US5648093 | JANSSEN PHARMS | Pharmaceutical and other dosage forms |
Jul, 2014
(9 years ago) | |
|
USRE39181 (Pediatric) | JANSSEN PHARMS | Aqueous risperidone formulations |
Jan, 2015
(9 years ago) | |
|
US5453425 (Pediatric) | JANSSEN PHARMS | Risperidone oral formulation |
Jan, 2015
(9 years ago) | |
|
US5648093 (Pediatric) | JANSSEN PHARMS | Pharmaceutical and other dosage forms |
Jan, 2015
(9 years ago) | |
| US6224905 | JANSSEN PHARMS | Biconvex rapidly disintegrating dosage forms |
Jun, 2017
(6 years ago) | |
|
US6224905 (Pediatric) | JANSSEN PHARMS | Biconvex rapidly disintegrating dosage forms |
Dec, 2017
(6 years ago) | |
Drugs and Companies using RISPERIDONE ingredient
Market Authorisation Date: 10 June, 1996
Treatment: NA
Dosage: SOLUTION;ORAL; TABLET, ORALLY DISINTEGRATING;ORAL
RISPERDAL family patents
17. Risperdal Consta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7547452 | JANSSEN PHARMS | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
Nov, 2013
(10 years ago) | |
| US6368632 | JANSSEN PHARMS | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
Nov, 2013
(10 years ago) | |
| US5965168 | JANSSEN PHARMS | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
Nov, 2013
(10 years ago) | |
| US6110921 | JANSSEN PHARMS | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
Nov, 2013
(10 years ago) | |
|
US6110921 (Pediatric) | JANSSEN PHARMS | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
May, 2014
(9 years ago) | |
|
US7547452 (Pediatric) | JANSSEN PHARMS | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
May, 2014
(9 years ago) | |
|
US5965168 (Pediatric) | JANSSEN PHARMS | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
May, 2014
(9 years ago) | |
|
US6368632 (Pediatric) | JANSSEN PHARMS | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
May, 2014
(9 years ago) | |
| US5688801 | JANSSEN PHARMS | Method of inhibiting neurotransmitter activity using microencapsulated 3-piperidiny2-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
Nov, 2014
(9 years ago) | |
|
US5688801 (Pediatric) | JANSSEN PHARMS | Method of inhibiting neurotransmitter activity using microencapsulated 3-piperidiny2-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
May, 2015
(8 years ago) | |
| US5916598 | JANSSEN PHARMS | Preparation of biodegradable, biocompatible microparticles containing a biologically active agent |
May, 2017
(6 years ago) | |
| US5792477 | JANSSEN PHARMS | Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent |
May, 2017
(6 years ago) | |
| US6403114 | JANSSEN PHARMS | Preparation of biodegradable, biocompatible microparticles containing a biologically active agent |
May, 2017
(6 years ago) | |
|
US5916598 (Pediatric) | JANSSEN PHARMS | Preparation of biodegradable, biocompatible microparticles containing a biologically active agent |
Nov, 2017
(6 years ago) | |
|
US5792477 (Pediatric) | JANSSEN PHARMS | Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent |
Nov, 2017
(6 years ago) | |
|
US6403114 (Pediatric) | JANSSEN PHARMS | Preparation of biodegradable, biocompatible microparticles containing a biologically active agent |
Nov, 2017
(6 years ago) | |
| US6194006 | JANSSEN PHARMS | Preparation of microparticles having a selected release profile |
Dec, 2018
(5 years ago) | |
| US6596316 | JANSSEN PHARMS | Preparation of microparticles having a selected release profile |
Dec, 2018
(5 years ago) | |
| US6379703 | JANSSEN PHARMS | Preparation of microparticles having a selected release profile |
Dec, 2018
(5 years ago) | |
|
US6194006 (Pediatric) | JANSSEN PHARMS | Preparation of microparticles having a selected release profile |
Jun, 2019
(4 years ago) | |
|
US6596316 (Pediatric) | JANSSEN PHARMS | Preparation of microparticles having a selected release profile |
Jun, 2019
(4 years ago) | |
|
US6379703 (Pediatric) | JANSSEN PHARMS | Preparation of microparticles having a selected release profile |
Jun, 2019
(4 years ago) | |
| US6667061 | JANSSEN PHARMS | Preparation of injectable suspensions having improved injectability |
May, 2020
(3 years ago) | |
|
US6667061 (Pediatric) | JANSSEN PHARMS | Preparation of injectable suspensions having improved injectability |
Nov, 2020
(3 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-597) | May 15, 2012 |
| New Indication(I-596) | May 15, 2012 |
Drugs and Companies using RISPERIDONE ingredient
Market Authorisation Date: 12 April, 2007
Treatment: Treatment of schizophrenia; Monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar i disorder
Dosage: INJECTABLE;INTRAMUSCULAR
RISPERDAL CONSTA family patents
18. Sporanox patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5633015 | JANSSEN PHARMS | Beads having a core coated with an antifungal and a polymer |
May, 2014
(9 years ago) | |
| US5707975 | JANSSEN PHARMS | Oral formulations on an antifungal |
Jan, 2015
(9 years ago) | |
| US6407079 | JANSSEN PHARMS | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation |
Jun, 2019
(4 years ago) | |
Drugs and Companies using ITRACONAZOLE ingredient
Market Authorisation Date: 11 September, 1992
Treatment: NA
Dosage: CAPSULE;ORAL; INJECTABLE;INJECTION
SPORANOX family patents
19. Spravato patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9592207 | JANSSEN PHARMS | Intranasal administration of ketamine to treat depression |
Mar, 2027
(2 years from now) | |
| US8785500 | JANSSEN PHARMS | Intranasal administration of ketamine to treat depression |
Mar, 2033
(8 years from now) | |
| US11446260 | JANSSEN PHARMS | Pharmaceutical composition of S-ketamine hydrochloride |
Mar, 2034
(9 years from now) | |
| US10869844 | JANSSEN PHARMS | Methods for the treatment of depression |
Sep, 2035
(11 years from now) | |
| US11311500 | JANSSEN PHARMS | Methods for the treatment of depression |
Sep, 2035
(11 years from now) | |
| US11173134 | JANSSEN PHARMS | Methods for the treatment of depression |
Sep, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| NCE*(NCE*) | Mar 05, 2024 |
| New Indication(I-840) | Jul 31, 2023 |
Drugs and Companies using ESKETAMINE HYDROCHLORIDE ingredient
Market Authorisation Date: 05 March, 2019
Treatment: Treatment of treatment-resistant depression in adult in conjunction with an oral antidepressant; Treatment of treatment-resistant depression in adults by nasally administering 56mg or 84mg of esketami...
Dosage: SPRAY;NASAL
SPRAVATO family patents
20. Topamax patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6503884 | JANSSEN PHARMS | Migraine treatment method using topiramate and related compounds |
Oct, 2015
(8 years ago) | |
| US7018983 | JANSSEN PHARMS | Treatment of migraine |
Oct, 2015
(8 years ago) | |
| US7498311 | JANSSEN PHARMS | Treatment of migraine |
Oct, 2015
(8 years ago) | |
| US5998380 | JANSSEN PHARMS | Treatment of migraine |
Oct, 2015
(8 years ago) | |
|
US6503884 (Pediatric) | JANSSEN PHARMS | Migraine treatment method using topiramate and related compounds |
Apr, 2016
(8 years ago) | |
|
US5998380 (Pediatric) | JANSSEN PHARMS | Treatment of migraine |
Apr, 2016
(8 years ago) | |
|
US7498311 (Pediatric) | JANSSEN PHARMS | Treatment of migraine |
Apr, 2016
(8 years ago) | |
|
US7018983 (Pediatric) | JANSSEN PHARMS | Treatment of migraine |
Apr, 2016
(8 years ago) | |
| US7125560 | JANSSEN PHARMS | Pharmaceutical composition of topiramate |
Mar, 2019
(5 years ago) | |
|
US7125560 (Pediatric) | JANSSEN PHARMS | Pharmaceutical composition of topiramate |
Sep, 2019
(4 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jul 15, 2014 |
| Pediatric Exclusivity(PED) | Jun 22, 2013 |
| M(M-54) | Dec 22, 2012 |
Drugs and Companies using TOPIRAMATE ingredient
Market Authorisation Date: 24 December, 1996
Treatment: Prophylactic treatment of migraine; Treatment of seizures
Dosage: TABLET;ORAL; CAPSULE;ORAL
TOPAMAX family patents
21. Topamax Sprinkle patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5998380 | JANSSEN PHARMS | Treatment of migraine |
Oct, 2015
(8 years ago) | |
| US6503884 | JANSSEN PHARMS | Migraine treatment method using topiramate and related compounds |
Oct, 2015
(8 years ago) | |
| US7018983 | JANSSEN PHARMS | Treatment of migraine |
Oct, 2015
(8 years ago) | |
| US7498311 | JANSSEN PHARMS | Treatment of migraine |
Oct, 2015
(8 years ago) | |
|
US5998380 (Pediatric) | JANSSEN PHARMS | Treatment of migraine |
Apr, 2016
(8 years ago) | |
|
US6503884 (Pediatric) | JANSSEN PHARMS | Migraine treatment method using topiramate and related compounds |
Apr, 2016
(8 years ago) | |
|
US7018983 (Pediatric) | JANSSEN PHARMS | Treatment of migraine |
Apr, 2016
(8 years ago) | |
|
US7498311 (Pediatric) | JANSSEN PHARMS | Treatment of migraine |
Apr, 2016
(8 years ago) | |
| US7125560 | JANSSEN PHARMS | Pharmaceutical composition of topiramate |
Mar, 2019
(5 years ago) | |
|
US7125560 (Pediatric) | JANSSEN PHARMS | Pharmaceutical composition of topiramate |
Sep, 2019
(4 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jul 15, 2014 |
| Pediatric Exclusivity(PED) | Jun 22, 2013 |
| M(M-54) | Dec 22, 2012 |
Drugs and Companies using TOPIRAMATE ingredient
Market Authorisation Date: 26 October, 1998
Treatment: Prophylactic treatment of migraine; Treatment of seizures
Dosage: CAPSULE;ORAL
TOPAMAX SPRINKLE family patents
22. Ultram patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6339105 | JANSSEN PHARMS | Analgesic regimen |
Oct, 2019
(4 years ago) | |
|
US6339105 (Pediatric) | JANSSEN PHARMS | Analgesic regimen |
Apr, 2020
(4 years ago) | |
Drugs and Companies using TRAMADOL HYDROCHLORIDE ingredient
Market Authorisation Date: 03 March, 1995
Treatment: A titration dosing regimen for the treatment of pain using an initial dose of about 25mg
Dosage: TABLET;ORAL
ULTRAM family patents
23. Xarelto patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7585860 | JANSSEN PHARMS | Substituted oxazolidinones and their use in the field of blood coagulation |
Dec, 2020
(3 years ago) | |
| US7157456 | JANSSEN PHARMS | Substituted oxazolidinones and their use in the field of blood coagulation |
Aug, 2024
(4 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7592339 | JANSSEN PHARMS | Substituted oxazolidinones and their use in the field of blood coagulation |
Dec, 2020
(3 years ago) | |
| US9415053 | JANSSEN PHARMS | Solid, orally administrable pharmaceutical composition |
Nov, 2024
(6 months from now) | |
|
US7157456 (Pediatric) | JANSSEN PHARMS | Substituted oxazolidinones and their use in the field of blood coagulation |
Feb, 2025
(10 months from now) | |
|
US9415053 (Pediatric) | JANSSEN PHARMS | Solid, orally administrable pharmaceutical composition |
May, 2025
(1 year, 15 days from now) | |
| US9539218 | JANSSEN PHARMS | Prevention and treatment of thromboembolic disorders |
Feb, 2034
(9 years from now) | |
|
US9539218 (Pediatric) | JANSSEN PHARMS | Prevention and treatment of thromboembolic disorders |
Aug, 2034
(10 years from now) | |
| US10828310 | JANSSEN PHARMS | Reducing the risk of cardiovascular events |
Jan, 2039
(14 years from now) | |
|
US10828310 (Pediatric) | JANSSEN PHARMS | Reducing the risk of cardiovascular events |
Jul, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-867) | Aug 23, 2024 |
| Pediatric Exclusivity(PED) | Feb 23, 2025 |
| New Indication(I-824) | Oct 11, 2021 |
| New Dosing Schedule(D-168) | Oct 27, 2020 |
| New Indication(I-810) | Oct 11, 2022 |
| M(M-284) | Mar 10, 2023 |
| New Indication(I-660) | Nov 02, 2015 |
| New Indication(I-661) | Nov 02, 2015 |
| New Indication(I-662) | Nov 02, 2015 |
| New Chemical Entity Exclusivity(NCE) | Jul 01, 2016 |
| New Indication(I-643) | Nov 04, 2014 |
Drugs and Companies using RIVAROXABAN ingredient
NCE-1 date: 24 February, 2024
Market Authorisation Date: 11 October, 2018
Treatment: Reduction of risk of major cardiovascular events (cv death, mi, and stroke) in chronic cad or pad; Treatment of venous thromboembolism (vte) and the reduction in the risk of recurrent vte in pediatric...
Dosage: TABLET;ORAL; FOR SUSPENSION;ORAL
XARELTO family patents